SCN1A rs2298771 TT genotype improved antiseizure medication response (p=0.044) and CACNA2D2 rs56287038 T allele conferred resistance (p=0.012), though significance was lost after FDR correction.
Are genetic variants in CACNA2D2, SCN1A, and SCN1B associated with antiseizure medication response in Turkish epilepsy patients?
Variants in CACNA2D2 and SCN1A may be associated with antiseizure medication response in Turkish epilepsy patients, though these exploratory findings require confirmation.
Introduction: Epilepsy is a chronic neurological disorder characterized by recurrent seizures, with variants in ion channel genes such as SCN1A, SCN1B, and CACNA2D2 implicated in neuronal excitability. This research aims to explore genetic polymorphisms in the SCN1A, SCN1B, and CACNA2D2 genes among Turkish epilepsy patients and assess their impact on responsiveness to antiseizure medications (ASMs). Methods: Targeted next-generation sequencing (tNGS) was applied to genomic DNA from 29 patients. Results: Common 15 variants were analyzed in CACNA2D2 (rs2239801, rs56287038), SCN1A (rs2298771, rs3032638, rs11394960, rs67636132, rs566839, rs1461193, rs6432861, rs2020318) and SCN1B (rs72556351, rs2278995, rs557140301, rs67701503, rs55742440). A statistically significant difference in ASM response was observed in the recessive model of SCN1A rs2298771: C>T (TT vs. CC+CT) (p=0.044), with the TT genotype associated with improved response. CACNA2D2 rs56287038:G>T showed significance in the allelic model (p=0.012); the T allele was found only in resistant patients. SCN1A haplotype analysis revealed reduced C allele frequency in responders (p=0.041). The CT (rs2298771+rs2020318), CG (rs2298771+rs1461193), and CC (rs2298771+rs6432861) haplotypes also showed considerable differences among groups (p=0.041, p=0.023, p=0.041, respectively). Moreover, CTG (rs2298771+rs2020318+rs1461193), CCG (rs2298771+rs6432861+rs1461193), and CTCG (rs2298771+rs2020318+rs6432861+rs1461193) haplotypes were significantly associated with treatment response (p=0.023, p=0.023, p=0.022). However, none of these associations remained statistically significant after false discovery rate (FDR) correction, and all findings should therefore be interpreted as exploratory. Conclusion: CACNA2D2 rs56287038:G>T and SCN1A rs2298771:C>T may effect ASM response.
Todurga-Seven et al. (2026) studied this question. SCN1A rs2298771 TT genotype improved antiseizure medication response (p=0.044) and CACNA2D2 rs56287038 T allele conferred resistance (p=0.012), though significance was lost after FDR correction.